These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta. Sternberg Z; Chadha K; Lieberman A; Drake A; Hojnacki D; Weinstock-Guttman B; Munschauer F J Neuroinflammation; 2009 Oct; 6():28. PubMed ID: 19825164 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the immunomodulatory effects of the plant sterol beta-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients. Desai F; Ramanathan M; Fink CS; Wilding GE; Weinstock-Guttman B; Awad AB Int Immunopharmacol; 2009 Jan; 9(1):153-7. PubMed ID: 19022404 [TBL] [Abstract][Full Text] [Related]
4. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540 [TBL] [Abstract][Full Text] [Related]
5. Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Anand SP; Selvaraj P Clin Immunol; 2009 Oct; 133(1):126-31. PubMed ID: 19615945 [TBL] [Abstract][Full Text] [Related]
6. Expression of TNF-alpha mRNA by peripheral blood mononuclear cells of multiple sclerosis patients treated with IFN-beta 1A. Sarchielli P; Critelli A; Greco L; Sokola E; Floridi A; Gallai V Cytokine; 2001 Jun; 14(5):294-8. PubMed ID: 11444910 [TBL] [Abstract][Full Text] [Related]
7. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607 [TBL] [Abstract][Full Text] [Related]
8. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Kieseier BC; Archelos JJ; Hartung HP Arch Neurol; 2004 Jun; 61(6):929-32. PubMed ID: 15210533 [TBL] [Abstract][Full Text] [Related]
9. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668 [TBL] [Abstract][Full Text] [Related]
10. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793 [TBL] [Abstract][Full Text] [Related]
12. Synergistic immune responses induced by endogenous retrovirus and herpesvirus antigens result in increased production of inflammatory cytokines in multiple sclerosis patients. Brudek T; Christensen T; Hansen HJ; Petersen T; Møller-Larsen A Scand J Immunol; 2008 Mar; 67(3):295-303. PubMed ID: 18261041 [TBL] [Abstract][Full Text] [Related]
13. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Bernal F; Elias B; Hartung HP; Kieseier BC Mult Scler; 2009 Jun; 15(6):721-7. PubMed ID: 19383643 [TBL] [Abstract][Full Text] [Related]
14. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. Singh MK; Scott TF; LaFramboise WA; Hu FZ; Post JC; Ehrlich GD J Neurol Sci; 2007 Jul; 258(1-2):52-9. PubMed ID: 17467740 [TBL] [Abstract][Full Text] [Related]
15. The effect of season on cytokine expression in multiple sclerosis and healthy subjects. Stewart N; Taylor B; Ponsonby AL; Pittas F; van der Mei I; Woods G; Walters H J Neuroimmunol; 2007 Aug; 188(1-2):181-6. PubMed ID: 17628701 [TBL] [Abstract][Full Text] [Related]
16. Interferon-beta: mechanism of action and dosing issues. Markowitz CE Neurology; 2007 Jun; 68(24 Suppl 4):S8-11. PubMed ID: 17562848 [TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1. Sanna A; Huang YM; Arru G; Fois ML; Link H; Rosati G; Sotgiu S Mult Scler; 2008 Nov; 14(9):1199-207. PubMed ID: 18653740 [TBL] [Abstract][Full Text] [Related]
18. Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis. Angelucci F; Mirabella M; Caggiula M; Frisullo G; Patanella K; Sancricca C; Nociti V; Tonali PA; Batocchi AP Peptides; 2005 Nov; 26(11):2289-93. PubMed ID: 16269354 [TBL] [Abstract][Full Text] [Related]
19. The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Hedegaard CJ; Krakauer M; Bendtzen K; Sørensen PS; Sellebjerg F; Nielsen CH Clin Immunol; 2008 Oct; 129(1):80-9. PubMed ID: 18653385 [TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory properties of Achyrocline satureioides (Lam.) D.C. infusion: a study on human leukocytes. Cosentino M; Bombelli R; Carcano E; Luini A; Marino F; Crema F; Dajas F; Lecchini S J Ethnopharmacol; 2008 Mar; 116(3):501-7. PubMed ID: 18280072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]